Sign up for Table of Contents Alerts.
Email this page
Print this page
News
John E. Niederhuber, Chief Operating Officer at the NCI
NA
volume 4 | issue 10
October 2005Pages: 1049
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
HHS secretary Michael Leavitt named John Niederhuber as Chief Operating Officer at the National Cancer Institute. This announcement followed an announcement by Dr. Andrew Von Eschenbach on September 30, 2005 that he plans to take a leave of absence from his position as Director of the National Cancer Institute as he became the acting FDA commissioner. Dr. Niederhuber, a senior academic surgeon and immunologist will handle the day-to-day operating activities at the NCI. He has served as Chair of the NCI NCAB and also as the Director for Translational and Clinical Sciences at the NCI. Niederhuber is on leave from his position as Director of the University of Wisconsin Comprehensive Cancer Center where he has been since 1997. Prior to that he was the Chair of Surgery at Stanford, a position he was recruited to in 1991. Dr. Niederhuber obtained his M.D. from Ohio State University in 1964 and served on the faculty at Johns Hopkins University School of Medicine from 1987-1991. He completed a Surgery Residency at the University of Michigan and was a Visiting Scientist at the Karolinska Institute in Sweden. Dr. Niederhuber has authored over 100 papers listed in PubMed and is an Editor of the widely-used textbook "Clinical Oncology." Dr. Niederhuber pioneered an implantable drug delivery system for continuous hepatic arterial infusion of chemotherapy for patients with liver metastases from colorectal cancer and was the first to implant venous access devices commonly used by cancer patients receiving chemotherapy. Dr. Niederhuber's research has investigated the transcriptional and translational regulation of a B-lymphocyte protein tyrosine kinase BLK, its role in signal transduction, and its oncogenic properties and has worked on developing a mouse model for chemically induced pancreatic ductal adenocarcinoma.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.